文献速递间质性肺疾病

抗αvβ6单克隆抗体治疗特发性肺纤维化的IIb期随机临床研究

A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis.
PubMed 文献 · Am J Respir Crit Care Med · 2022-01-01

这项IIb期随机双盲安慰剂对照试验评估了抗αvβ6单克隆抗体BG00011在特发性肺纤维化(IPF)患者中的疗效与安全性。因不良事件失衡和缺乏临床获益而提前终止,第26周探索性分析显示BG00011组与安慰剂组FVC变化无显著差异,但BG00011组显示纤维化恶化趋势及更多严重不良事件。结果不支持BG00011的继续临床开发。

要点

  • BG00011组与安慰剂组第26周FVC变化无显著差异(P=0.268)。
  • BG00011组治疗后纤维化恶化比例更高(44.4% vs 18.2%)。
  • BG00011组严重不良事件更常见,包括4例死亡。

核心结论

  • 结果不支持BG00011的继续临床开发。
  • 需要进一步研究识别改变IPF炎症和纤维化通路的新治疗策略。

研究设计与样本

  • IIb期随机、双盲、安慰剂对照试验。
  • IPF患者(FVC≥50%预计值,接受或不接受背景治疗)按1:1随机接受每周一次皮下BG00011 56 mg或安慰剂。
  • 主要终点为第52周FVC较基线变化;因试验提前终止,第26周作为探索性分析评估终点。

主要发现

  • 第26周,BG00011组(n=20)与安慰剂组(n=23)FVC较基线变化的最小二乘均值(SE)分别为-0.097 L(0.0600)和-0.056 L(0.0593),P=0.268。
  • 第26周后,BG00011组患者显示恶化趋势。
  • 治疗结束时高分辨率CT显示纤维化恶化:BG00011组18例中8例(44.4%),安慰剂组22例中4例(18.2%)。
  • IPF急性加重/或进展报告于13例患者,均在BG00011组。
  • BG00011组严重不良事件更频繁,包括4例死亡。

局限性

  • 试验因不良事件失衡和缺乏临床获益而提前终止。
  • 第26周分析为探索性分析。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Rationale: Treatment options for idiopathic pulmonary fibrosis (IPF) are limited. Objectives: To evaluate the efficacy and safety of BG00011, an anti-αvβ6 IgG1 monoclonal antibody, in the treatment of patients with IPF. Methods: In a phase IIb randomized, double-blind, placebo-controlled trial, patients with IPF (FVC ⩾50% predicted, on or off background therapy) were randomized 1:1 to once-weekly subcutaneous BG00011 56 mg or placebo. The primary endpoint was FVC change from baseline at Week 52. Because of early trial termination (imbalance in adverse events and lack of clinical benefit), endpoints were evaluated at Week 26 as an exploratory analysis. Measurements and Main Results: One hundred six patients were randomized and received at least one dose of BG00011 (n = 54) or placebo (n = 52). At Week 26, there was no significant difference in FVC change from baseline between patients who received BG00011 (n = 20) or placebo (n = 23), least squares mean (SE) -0.097 L (0.0600) versus -0.056 L (0.0593), respectively (P = 0.268). However, after Week 26, patients in the BG00011 group showed a worsening trend. Eight (44.4%) of 18 who received BG00011 and 4 (18.2%) of 22 who received placebo showed worsening of fibrosis on high-resolution computed tomography at the end of treatment. IPF exacerbation/or progression was reported in 13 patients (all in the BG00011 group). Serious adverse events occurred more frequently in BG00011 patients, including four deaths. Conclusions: The results do not support the continued clinical development of BG00011. Further research is warranted to identify new treatment strategies that modify inflammatory and fibrotic pathways in IPF. Clinical trial registered with www.clinicaltrials.gov (NCT03573505).

来源:Am J Respir Crit Care Med,查看原文。版权归原作者所有。

引用

  1. Raghu G, Mouded M, Chambers DC, et al. A Phase IIb Randomized Clinical Study of an Anti-αvβ6 Monoclonal Antibody in Idiopathic Pulmonary Fibrosis. Am J Respir Crit Care Med. 2022. PMID: 35771569. doi:10.1164/rccm.202112-2824OC

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。